The progression of severe aplastic anemia to hypoplastic leukemia in a long-term observation after the administration of pegylated rHuMGDF

Hematology Reports

Daisuke Okamura¹  Nobutaka Kawai¹  Akira Matsuda¹  Tomoya Maeda¹  Maho Ishikawa¹  Norio Asou¹  Masami Bessho¹ 

[1] Department of Hemato-Oncology, Saitama Medical University International Medical Center, Hidaka, Saitama

关键词: Aplastic anemia;    acute myeloid leukemia;    thrombopoietin;    clonal evolution;   

DOI  :  10.4081/hr.2018.7679

学科分类：血液学

来源: Pagepress

【 摘 要 】

Thrombopoietin (TPO) is a critical regulator of hematopoiesis. We previously reported that a severe aplastic anemia (SAA) who received a short-term administration of pegylated recombinant human megakaryocyte growth and development factor (rHuMGDF). A trilineage hematologic response was induced, however the patient was diagnosed with leukemia after nine years and eight months from administration of rHuMGDF. In recent reports, somatic mutations in myeloid cancer candidate genes were present in one-third of the AA. A mutant clone may be expanded by rHuMGDF in our patient. The long-term safety of patients treated with TPO and eltrombopag remains unknown. Careful observations are warranted hereafter.

【 授权许可】

CC BY-NC